ROCKVILLE, Md., Oct. 18, 2019 /PRNewswire/ — American Gene Technologies (AGT) announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, which is potentially a single-dose, lentiviral vector-based gene therapy developed for the purpose of eliminating HIV from people infected with the disease.
Image: https://www.prnewswire.com
{iframe}https://www.prnewswire.com/news-releases/ind-application-submission-to-fda-for-phase-1-trial-of-genetically-modified-autologous-cell-therapy-for-hiv-announced-by-american-gene-technologies-300941349.html{/iframe}